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INTRODUCTION
Therapeutic plasma exchange (TPE) is an extra-
corporeal blood purification technique able to re-
move from plasma macromolecules not removable 
by means of haemodialysis and/or to replace defi-
cient plasma factors [1]. About twenty years after 
the birth and the empirical application of TPE [2], 
authoritative studies typed the diseases in which TPE 
may be useful and looked for guidelines in indica-
tions for TPE. Four categories of diseases had been 
identified [1, 3, 4]: the first category includes the dis-
eases in which controlled trials suggested TPE as the 
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Summary. Therapeutic plasma exchange is an extra-corporeal technique able to remove from blood 
macromolecules and/or replace deficient plasma factors. It is the treatment of choice in hyperviscos-
ity syndrome, due to the presence of quantitatively or qualitatively abnormal plasma proteins such 
as paraproteins. In spite of a general consensus on the indications to therapeutic plasma exchange 
in hyperviscosity syndrome, data or guide lines about the criteria to plan the treatment are still lack-
ing. We studied the rheological effect of plasma exchange in 20 patients with plasma hyperviscosity 
aiming to give data useful for a rational planning of the treatment. Moreover, we verified the clinical 
applicability of the estimation of plasma viscosity by means of Kawai’s equation. Plasma exchange 
decreases plasma viscosity about 20-30% for session. Only one session is required to normalize 
plasma viscosity when it is < 2.2 mPas, whereas a maximum of 3 sessions are required when it is 
> 2.2 till to 6 mPas. A fourth session is useless, especially if  the inter-session interval is < 15 days. 
By means of a polynomial equation, knowing basal-plasma viscosity and the disease of a patient, 
we can calculate the decrease of viscosity obtainable by each session of plasma exchange then the 
number of session required to normalize the viscosity. Kawai’s equation is able to evaluate plasma 
viscosity in healthy volunteers, but it is not clinically reliable in paraproteinemias. 
Key words: therapeutic apheresis, plasma viscosity, hyperviscosity syndrome, plasma exchange. 
 
Riassunto (Plasma exchange nella sindrome da iperviscosità acuta e cronica: approccio reologico e 
studio di linee guida). Il plasma exchange è una tecnica terapeutica extracorporea che consente di 
rimuovere dal sangue macromolecole lesive e/o supplementare fattori plasmatici carenti. Costituisce 
il trattamento di elezione della sindrome da iperviscosità, dovuta alla presenza nel plasma di pro-
teine quantitativamente o qualitativamente anomale. Nonostante l’ampio consenso all’impiego del 
plasma exchange nella sindrome da iperviscosità, non vi sono al momento istruzioni operative o linee 
guida per la pianificazione del trattamento. Abbiamo studiato gli effetti emoreologici del plasma 
exchange in 20 pazienti con iperviscosità plasmatica al fine di ricavare dati utili per una pianificazi-
one razionale della terapia aferetica. Abbiamo inoltre verificato l’applicabilità clinica della formula 
di Kawai per il calcolo teorico della viscosità plasmatica. Una singola seduta di plasma exchange 
riduce la viscosità plasmatica del 20-30%. Una sola seduta normalizza la viscosità plasmatica quan-
do questa è < 2.2 mPas, mentre sono necessarie 3 sedute quando la viscosità è > 2.2, fino a 6 mPas. 
Una quarta seduta non risulta utile, specie se eseguita ad un intervallo < 15 giorni. Conoscendo 
la viscosità plasmatica iniziale e la patologia del paziente, utilizzando un’equazione polinomiale, è 
possibile calcolare il decremento di viscosità per ogni seduta ed il numero di sedute necessarie per 
normalizzarla. L’equazione di Kawai non consente un calcolo attendibile della viscosità plasmatica 
nei pazienti con paraproteinemia. 
Parole chiave: aferesi terapeutica, viscosità plasmatica, sindrome da iperviscosità, plasma exchange.
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standard therapy i.e. thrombotic thrombocytopenic 
purpura or hyperviscosity; second category includes 
the diseases for which there is available evidence 
suggesting efficacy of TPE, i.e. systemic vasculitis, 
or myeloma-paraproteinemias; third category in-
cludes the disorders which have not adequately tests 
of efficacy of TPE at this time, i.e. progressive sys-
temic sclerosis or multiple sclerosis; fourth category 
includes the disease for which it’s not demonstrated 
efficacy of TPE in controlled trials, i.e. psoriasis or 
amyotrophic lateral sclerosis. Despite of a large con-
sensus on guidelines concerning the indications to 
TPE, data or guidelines about the criteria to plan 
the treatment are still lacking [4]. 
We studied the use of TPE in dysproteinemias 
which can cause different kidney lesions (i.e. cast 
nephropathy, light chain deposition disease) and/or 
plasma hyperviscosity. Acute hyperviscosity syn-
drome (HS) can occur when the normal plasma vis-
cosity (PV) of 1.4 mPas increse up to 4-5 mPas and 
it is more common in Waldenström’s macroglob-
ulinemia, than multiple myeloma or cryoglobulins 
[5]. In particular, acute HS can appear when plas-
matic IgM is > 5 gr/dL or IgG3 and monomeric 
IgA > 4-5 gr/dL or polimeric IgA > 10-11 gr/dL. 
Clinical manifestations of acute HS are due to both 
vascular occlusion and impaired haemostasis; it in-
cludes ocular, neurological and cardiovascular dys-
functions and bleeding [6]. Really, acute HS is a very 
rare event whereas we often observe patients with 
asimptomatic light or mild plasma hyperviscosity, 
2-3 mPas, due to paraproteins, high levels of immu-
noglobulins, alfaglobulin or lipids. TPE is the trat-
ment of choice of acute HS and it is however able to 
effectively and rapidly correct plasma viscosity dur-
ing the period that other therapeutic interventions 
such as chemotherapy take effect. It’s well known 
that the efficiency of TPE is different for different 
molecules and ranges from 15 to 75%; it is highest 
for IgM because of their prevalent intravascular dis-
tribution and is 4-5 fold lower for IgG because of 
their wide extravascular distribution [1, 7]. In spite 
of this, quantitative data about the rheological ef-
fect of TPE are lacking and parameters regarding 
the start, the frequency and the end point of TPE 
are usually empirically settled. 
Aims of the study were: a) to get a status-report 
of our clinical behaviour; b) to quantify the rheo-
logical efficacy of TPE; c) to give data useful in plan-
ning TPE; d) to create a model for computation the 
number of TPE-sessions required to normalizing PV 
in each patient on the basis of his basal PV and his 
disease; e) to verify the clinical applicability of the es-
timation of PV by means of Kawai’s equation (KE). 
In fact, KE could be very helpful in hospital units 
where viscometers or rheometers are unavailable.
METHODS
We studied 20 patients undergone to TPE for 
a total of 51 treatments. The mean age of the pa-
tients was 65±14 years. They were undergoing to 
TPE because of multiple myeloma (MM) 30%, 
Waldenström’s macroglobulinemia (WM) 25%, 
monoclonal gammopathy of undetermined signifi-
cance (MGUS) 5%, cryoglobulinemia (CG) 25%, 
other inflammatory disease (ID) 15% with increased 
alfa-globulins and/or polyclonal immunoglobulins, 
such as collagenopathies.
The technique of plasma exchange was: continu-
ous flow system; mean volume of exchange 40 ml/
kg/session; acid-citrate-dextrose as anticoagulant. 
Replacement solution composition: albumin 3.3%, 
Na 154 mEq/L, K 3 mEq/L, Ca 2.5 mEq/L.
We measured PV with the rheometer Hakke-
CV100 (Hakke GmbH, Karlsruhe, Germany) at 
even temperature of 37 °C and shear rate 300 s-1, ac-
cordingly with the indications of the International 
Committee for Standardization in Haematology 
standards [8]. The measures had been done pre and 
post TPE. In CG, the PV had been measured at tem-
perature of 30 °C too. 
Moreover, we estimated the rough PV pre and post 
TPE and in 30 healthy volunteers by means of the 
equation of Kawai [9, 10]: 
PV = 0.204 + (0.177×PT)
where PV is plasma viscosity expressed as mPas and 
PT are plasma proteins expressed as g/dL.
All the data concerning PV were analyzed after the 
end point of TPE program, therefore results and val-
ues of PV did not influence planning and frequency 
of the treatments.
RESULTS AND DISCUSSION
First of all, we could obtain a status-report of our 
clinical behaviour at this time. Empirically, we pre-
scribed 3 TPE for patients with MGUS, 4 for MM 
and 5 for WM. In CG and ID we tend to prescribe 
a major number of treatments, till to 7. The interval 
between the treatments was less than a week (from 1 
to 5 days) for the first 4 sessions, and usually above 
15 days for following sessions. The end point of TPE 
was empirically decided for patients with parapro-
teinemias, whereas for the other diseases, included 
CG, it was determined especially on the basis of 
laboratory and clinical signs of remission.
Figure 1 shows the rheological effects of each TPE-
session. The rheological efficiency (RE) of TPE in 
decreasing PV was major when major was basal-PV. 
By the analysis of the figure we can roughly foresee 
that the normalization of a basal-PV < 2.2 mPas re-
quires only one TPE-session; whereas, the required 
sessions are almost 2 when basal-PV is > 2.2 till 
up to 6 mPas. Nevertheless, it must be considered 
that the RE of each session is varying during a TPE 
program. In fact, the RE tended to progressively 
decrease in relation to the progressive decrease of 
PV. Really, as shown in Figure 2a, a significant fall 
of RE appeared only during the fourth consecutive 
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session of TPE. Moreover, TPE is very able to re-
move molecules, but it don’t stop their production 
and PV could tend to rise during the break between 
the sessions. Figure 2b shows the mean increasing 
of PV between consecutive sessions of TPE, due 
to redistribution and/or neo-production of plasma 
proteins and/or paraproteins. Really, PV reached 
again to the starting levels only in occasion of the 
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Fig. 1 | Rheological effects of each therapeutic plasma exchange session. Higher is basal plasma viscosity therefore grater is the decrease 
of viscosity post apheresis. A single one session of plasma exchange normalizes plasma viscosity when it is < 2.2 mPas. Whereas 2 ses-
sions sare required when plasma viscosity is > 2.2 till to 6 mPas.
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Fig. 2 | a) the fall in rheological efficiency of plasma exchange (DPV pre-post) was significant only during the fourth consecutive ses-
sion. It increased again after an interval ≥15 days, when plasma viscosity (PV) was increased too. Whereas, the break between the first 
four sessions was ≤ 5 days. b) mean plasma viscosity pre-plasma exchange (PrePV) during consecutive session. PrePV progressively 
decreased till to a nadir after the third session and increase again after the break ≥15 days. 
174 Marco Ballestri, Federica Ferrari, Riccardo Magistroni, et al.
fifth session, usually performed ≥15 days after the 
fourth. Nevertheless, we take into account that rate 
of productions can be very variable and depending 
to type and severity of the disease and to medical 
treatments such as chemotherapy. 
The study of rheological effect of the TPE-sessions 
in the different diseases confirmed the greatest efficacy 
in decreasing PV in WM (about 33 ± 0.12 %), because 
of the prevalent intravascular distribution of IgM [1]. 
The decrease was 20 ± 0.21% in MM, 17 ± 0.04 % in 
MGUS, 19 ± 0.12 % in CG and 33 ± 0.09 % in ID. 
The high rheological efficiency of TPE obtained in ID 
could be explained by the complex genesis of hyper-PV, 
probably due to synergic effect of alfa- and gamma-
globulins. On the contrary, in CG, the influence of im-
munoglobulins became evident only when we measured 
PV at temperature 30 °C, whereas at 37 °C, the hyper-
PV seemed mainly due to alfa-globulins. Nevertheless, 
because of the little number of cryoglobulinemic pa-
tients, we did not obtain the statistical significance. 
The analysis of PV-decreasing in function of ba-
sal-PV showed a polynomial relation expressed by 
the following equation (Figure 3):
DPV = (0.0531 PV Pre2) + (0.370 PV Pre) - 0,332 where 
DVP is the gradient of PV pre-post a single session of 
TPE and PV Pre is PV at the start of the session. 
The standard error of this equation is 0,1 (R2 = 0.96; 
p = 000). The error lightly increases when PV Pre is 
< 2 mPas, but in this case only one session of TPE is 
sufficient to normalize PV and no long planning is re-
quest. Testing the correlation in the different diseases, 
we could confirmed a more closely correlation only 
in the lympho-immunoproliferative disorders and we 
could be define more specific numeric coefficients to 
reduce the standard error. In particular, DPV = (0.045 
PV Pre2) + (0.4485 PV Pre) - 0.4533 for MM (R2 = 
0.99; p = 0.000); DPV = (0.0347 PV Pre2) + (0.4584 
PV Pre) - 0.4307 for WM (R2 = 0.95; p = 0.000) and 
DPV = (0.0499 PV Pre2) + (0.403 PV Pre) - 0.3949 (R2 
= 0.97; p = 0.000) for MM + WM.
KE was perfectly reliable when applied to estimate 
PV in healthy volunteers and in patients affected by 
ID (Table 1). On the contrary, it was not reliable 
in calculating PV pre-TPE in patients with parap-
roteinemias because of an evident undervaluation. 
KE was again reliable post TPE-session, that is after 
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Fig. 3 | Correlation between gradi-
ent of plasma viscosity pre and post 
apheresis (DPV) in function of basal 
plasma viscosity (PV). It’s possible 
to roughly calculate a polynomial 
relation by mean of which the DPV 
of each plasma exchange can be pre-
dicted. Then, the number of sessions 
required to normalize PV can be es-
timated. a) Curve calculated on the 
basis of the overall cases. b) Curve 
calculated on the basis of GM and 
MM patients. 
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removal of paraproteins from plasma. The absence 
of statistic significance in MM and MGUS group 
was due respectively to the high variance and to the 
small dimension of the sample. These observations 
confirm that hyperviscosity in paraproteinemias is 
due not only to the concentrations of paraproteins 
[5], but also to their abnormal shape, abnormal po-
lymerisation, and/or interaction with other plasma-
proteins. On the contrary, the increase of PV in ID is 
due to an excess of normal plasma proteins (mainly 
alfa-globulins and/or polyclonal immunoglobulins) 
and only their concentration influences PV. 
 
CONCLUSIONS
TPE is a useful technique able to rapidly correct HS 
and mainly decrease PV about 20-30% each session. 
Probably, the existing empirical approach to planning 
TPE-treatment in hyper-PV causes a little overdose 
of this therapy. Only one TPE-session is required to 
normalize PV when it is < 2.2 mPas, whereas a maxi-
mum of 2-3 session are required when it is > 2.2 till 
up to 6 mPas. In general, a fourth session is useless 
especially if the inter-session period is < 10-15 days. 
We can roughly calculate the decrease of PV obtain-
able by each TPE-session and the number of session re-
quired to normalize PV, knowing basal-PV and the dis-
ease of a patient. The polynomial equation suggested is: 
=(0.0499 PV Pre2)+(0.403 PV Pre)- 0.395. However it 
is possible to use more disease’s specific coefficients.
KE is not clinically reliable to evaluate PV in para-
proteinemias because paraproteins can influence PV 
by means of interaction mechanisms and independ-
ently by their concentrations.
Actually we are performing studies on larger popula-
tions, this effort will permit to develop a simply soft-
ware for automatic planning of TPE-treatment in HS.
Moreover, we need studies able to clarify when the 
correction of hyper-PV is indicated. Acute HS is of 
very rare occurrence, therefore light or mild chronic 
asymptomatic hyper-PV is of very frequent observa-
tion in patients with paraproteins, inflammation dis-
orders, hyper-fibrinogenemia, hyper-lipoproteinemia, 
metabolic syndrome and so on. The rule of chronic 
hyperviscosity in stimulating endothelial responses is 
probably underestimated and we cannot exclude the 
existence of a chronic HS (CHS) able to impair mi-
crocirculation and promote progression of target or-
gan-damage. Probably, TPE will not be the treatment 
of choice for CHS: it will be a new venture. 
Submitted on invitation.
Accepted on 3 April 2007.
Table 1 | Difference between plasma viscosity (PV) measured (M) and roughly calculate with Kawai’s equation (KE)
PV Pre: PV pre plasma exchange; PV Post: PV post plasma exchange; HV: healthy volunteers; MM: multiple myeloma; WG: Waldenström’s macroglobuline-
mia, MGUS; monoclonal gammopathy of undetermined significance; CG: cryoglobulinemia; ID: other inflammatory diseases. Kawai’s equation (KE).
  HV	 All	 MM	 WM	 MGUS	 CG	 ID
PV Pre M (mPas) 1.47 ± 0.10 1.96 ± 0.99 2.94 ± 1.93 2.02 ± 0.43 1.42 ± 0.20 1.47 ± 0.27 1.70 ± 0.19
 KE 1.47 ± 0.06 1.58 ± 0.30 1.93 ± 0.26 1.66 ± 0.18 1.35 ± 0.01 1.25 ± 0.15 1.74 ± 0.12
 p n.s. 0:03 n.s. 0.008 n.s. 0:02 n.s.
PV Post M (mPas)  1.21 ± 0.23 1.20 ± 0.03 1.33 ± 0.27 1.18 ± 0.24 1.09 ± 0.21 1.22 ± 0.22
 KE  1.14 ± 0.18 1.64 ± 0.28 1.15 ± 0.03 1.07 ± 0.03 1.01 ± 0.08 1.19 ± 0.08
 p  n.s. n.s. n.s. n.s. n.s. n.s.
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